Umoja Biopharma
5 articles with Umoja Biopharma
-
BioSpace is proud to present its NextGen Bio “Class of 2022,” a list of up-and-coming life sciences companies in North America that recently launched.
-
BioSpace Movers & Shakers, Oct. 22
10/22/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Umoja Biopharma Appoints Biotech Industry Leader Clay Siegall, Ph.D. as Chairman of the Board
10/18/2021
Umoja Biopharma, an oncology company leveraging its proprietary integrated technologies to reprogram immune cells in vivo to create next-generation immunotherapies for the treatment of solid tumors and hematologic malignancies, announced the appointment of Clay Siegall, Ph.D. as its Chairman of the Board of Directors.
-
The 146,000 square foot facility will benefit Umoja Biopharma to eliminate crucial CAR-T production barriers. There’s a lot more going on, know everything here.
-
Immunotherapies are about to get safer, more effective, and even more accessible with the new biotech’s novel approach.